{
  "id": 1768146510347,
  "seqId": 82,
  "title": "FUNGAL KERATITIS: THE COMPLETE CLINICAL PLAYBOOK",
  "summary": "An exhaustive guide to the assessment, diagnosis, and multi-modal treatment of fungal keratitis. This resource covers clinical differentiators between yeast and filamentary infections, intensive topical and systemic protocols, and critical monitoring requirements for complex antifungal therapies.",
  "date": "2026-01-11T15:48:30.347Z",
  "data": {
    "title": "FUNGAL KERATITIS: THE COMPLETE CLINICAL PLAYBOOK",
    "summary": "An exhaustive guide to the assessment, diagnosis, and multi-modal treatment of fungal keratitis. This resource covers clinical differentiators between yeast and filamentary infections, intensive topical and systemic protocols, and critical monitoring requirements for complex antifungal therapies.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='40' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><circle cx='50' cy='50' r='15' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='1' stroke-dasharray='4'/><path d='M45 45 L35 35 M55 45 L65 35 M45 55 L35 65 M55 55 L65 65' stroke='hsl(215, 90%, 45%)' stroke-width='1.5' stroke-linecap='round'/><path d='M50 40 L50 30 M60 50 L70 50 M50 60 L50 70 M40 50 L30 50' stroke='hsl(215, 90%, 45%)' stroke-width='1' stroke-linecap='round'/><circle cx='50' cy='50' r='5' fill='hsl(215, 90%, 45%)' fill-opacity='0.3'/></svg>",
    "sections": [
      {
        "title": "Clinical Presentation: Yeast vs. Filamentary",
        "icon": "visibility",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Feature",
            "Yeast Infection",
            "Filamentary Fungal Infection"
          ],
          "rows": [
            [
              "Onset/Progression",
              "Insidious or rapid",
              "Usually insidious"
            ],
            [
              "Appearance",
              "Often localized with ‘button’ appearance",
              "Early: may be asymptomatic, intact epithelium, minimal corneal stromal infiltrate, mild AC inflammation."
            ],
            [
              "Later Signs",
              "Expanding stromal infiltrate",
              "Satellite lesions, feathery branching infiltrate, and immune ring."
            ],
            [
              "Severe Presentation",
              "Relatively small epithelial ulceration",
              "Ulceration, involvement of deeper corneal layers and Descemet’s membrane, white plaque on the endothelium, and severe AC inflammation (e.g. hypopyon)."
            ]
          ]
        }
      },
      {
        "title": "Clinical Warnings & Complications",
        "icon": "warning",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "NB In late infection, distinctive patterns may be lost; clinical appearance may resemble advanced bacterial keratitis.",
          "Complication: Limbal and scleral extension",
          "Complication: Corneal perforation",
          "Complication: Endophthalmitis (see E Post-operative endophthalmitis, pp. 370–2)",
          "Complication: 2° bacterial infections",
          "Complication: Infectious crystalline keratopathy"
        ]
      },
      {
        "title": "Assessment & Investigations",
        "icon": "biotech",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Perform early and adequate corneal scrapes (see Box 7.1).",
          "Stains: Gram (fungal walls), Giemsa (walls and cytoplasm).",
          "Special Stains: Grocott’s methenamine silver (GMS), PAS stain, and calcofluor white.",
          "Culture: Sabouraud dextrose agar (most fungi).",
          "Culture: Blood agar (for Fusarium).",
          "Culture Timeline: May require up to 14 days.",
          "Note: In vitro sensitivities are poorly predictive of in vivo sensitivity; little used clinically.",
          "If clinical suspicion is strong but investigations negative: consider confocal microscopy, corneal biopsy for histopathology, and PCR for fungal DNA."
        ]
      },
      {
        "title": "Treatment Principles",
        "icon": "emergency",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "green",
        "content": "Effective eradication of fungi is frequently difficult because of the deeply invasive nature of the infectious process. Identification of the organism must be a priority so as to ensure optimal choice of therapy."
      },
      {
        "title": "Initial Treatment Protocol",
        "icon": "medical_services",
        "type": "process",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "1. Admit the patient.",
          "2. Intensive topical broad-spectrum antifungals: non-preserved clotrimazole 1%, natamycin 5% (preserved only), or voriconazole 1%.",
          "3. Dosing: Hourly day and night for the first 72h.",
          "4. Avoid corticosteroids (reduce/stop if already on them).",
          "5. Oral analgesia and cycloplegia (e.g. preservative-free cyclopentolate 1% 3×/d)."
        ]
      },
      {
        "title": "Systemic Treatment Considerations",
        "icon": "pill",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Consider adding systemic antifungals (e.g., oral fluconazole or itraconazole).",
          "Indications: Severe disease (deep stromal lesions, threatened perforation, endophthalmitis).",
          "Indications: All immunocompromised patients.",
          "Topical treatment should be continued concurrently.",
          "Liaise with a microbiologist for drug selection, dosing, and monitoring advice."
        ]
      },
      {
        "title": "Agent Preferences & Severe Cases",
        "icon": "medication_liquid",
        "type": "remember",
        "layout": "half_width",
        "color_theme": "purple",
        "content": {
          "mnemonic": "DRUG SELECTION",
          "explanation": "Voriconazole: Preferred for suspected/proven candidal infection. Natamycin: Preferred for filamentary fungal infection. For severe/unresponsive disease: Add a second agent (e.g., preservative-free amphotericin 0.15% hourly day and night for the first 24h, then reducing to day only)."
        }
      },
      {
        "title": "Box 7.4: Systemic Dosing Regimens",
        "icon": "inventory",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Drug",
            "Dosing & Indications"
          ],
          "rows": [
            [
              "Oral Fluconazole (First line)",
              "50–100mg 1×/d for 7–14d. Effective against Candida and Aspergillus."
            ],
            [
              "Voriconazole (Resistant/Aspergillus)",
              "PO: 400mg 2×/d for two doses, then 200mg 2×/d (can increase to 300mg 2×/d). IV: 6mg/kg 2×/d for two doses, then 4mg/kg 2×/d."
            ],
            [
              "IV Flucytosine (Invasive Yeast)",
              "50mg/kg 4×/d; adjust as per plasma level monitoring."
            ]
          ]
        }
      },
      {
        "title": "Systemic Side Effects & Monitoring",
        "icon": "monitor_heart",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Renal dysfunction: associated with Voriconazole.",
          "Hepatotoxicity: associated with Fluconazole and Voriconazole.",
          "Blood disorders: associated with Flucytosine and Voriconazole.",
          "Mandatory Monitoring: FBC, U+E, and LFTs prior to starting and at least weekly during treatment.",
          "Dosing adjustment required for renal dysfunction.",
          "Plasma level monitoring is required for Flucytosine (see Table 7.9)."
        ]
      },
      {
        "title": "Ongoing Treatment & Recovery",
        "icon": "rehabilitation",
        "type": "process",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "1. Taper treatment according to clinical improvement.",
          "2. Be alert for relapse (common; signifies incomplete sterilization or reactivation).",
          "3. Prolonged Treatment: 12 weeks total.",
          "4. Healing Phase: Topical corticosteroids (e.g. PF dexamethasone 0.1% 1×/d) may be used under corneal specialist direction.",
          "5. Surgery: Consider PK (Penetrating Keratoplasty) for progressive disease or visually compromised eyes."
        ]
      },
      {
        "title": "Table 7.9: Antifungal Agents Classification",
        "icon": "fact_check",
        "type": "table",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": {
          "headers": [
            "Class",
            "Mechanism",
            "Examples"
          ],
          "rows": [
            [
              "Polyenes",
              "Destabilize cell wall",
              "Natamycin, amphotericin"
            ],
            [
              "Imidazoles",
              "Destabilize cell wall",
              "Clotrimazole, econazole, ketoconazole, miconazole"
            ],
            [
              "Triazoles",
              "Destabilize cell wall",
              "Itraconazole, voriconazole, fluconazole"
            ],
            [
              "Pyrimidines",
              "Cytotoxic",
              "Flucytosine"
            ]
          ]
        }
      }
    ]
  },
  "chapterId": "cornea",
  "_serverSynced": true
}